Events - 08 Mar 09:00FDA public meeting on vitiligo

Event

FDA public meeting on vitiligo

Silver Spring, MD, USA

UPDATE: FDA is announcing a new date for the meeting. The public meeting will be held on March 8, 2021 from 10 a.m. to 2:30 p.m. EST, in a virtual (online only) format. Please save this date and time if you are interested in attending this public meeting.

US Food and Drug Administration (FDA) is conducting its first public meeting on Patient-Focused Drug Development for Vitiligo. The meeting is intended to allow FDA to obtain patient perspectives on the impact of vitiligo, including on daily life, patient views on treatment approaches, and decision factors taken into account when selecting a treatment. 

Additional information about the meeting can be found on the meeting webpage. The webpage will be updated as meeting materials are developed, and registration will be available closer to the meeting date.

Please email the PFDD Staff at patientfocused@fda.hhs.gov if you have any questions.

FAQOther Questions

  • Does halo nevi affect vitiligo development?

    Halo nevi (also known as Sutton's nevi) are characterized by a mole that's surrounded by a ring of depigmented or lighter skin. While both halo nevi and vitiligo involve the des...

  • Is there a special diet for vitiligo?

    Recent research highlights the potential of diet and nutrition in managing vitiligo, offering an alternative where traditional therapies may be lacking. However, the relationshi...

  • Vitiligo and Pregnancy

    Pregnancy with vitiligo? The good news: vitiligo itself doesn’t make pregnancy unsafe. Most women stay stable (some even improve), though flares can pop up after birth — usually...